Facebook Instagram Twitter Linkedin Youtube Podcast

Duchenne News Tags: Entrada Therapeutics

Search
Tags
Tags
Antisense Therapeutics Astellas Pharma Avidity Biosciences BioMarin Pharmaceuticals Catalyst Pharmaceuticals Dyne Therapeutics Edgewise Therapeutics Entrada Therapeutics FDA FibroGen Italfarmaco NS Pharma PepGen Pliant Therapeutics PTC Therapeutics REGENXBIO Santhera Sarepta Therapeutics Solid Biosciences Wave Life Sciences
November 27, 2023

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

Entrada announces the completion of dosing for the first and second cohorts of its Phase 1 clinical trial, ENTR-601-44-101.
Read More
November 7, 2023

Entrada Therapeutics Reports Third Quarter 2023 Financial Results

Entrada reports third quarter 2023 financial results and more business updates.
Read More
September 21, 2023

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne

Entrada announces the first participant has been dosed in its Phase 1 clinical trial evaluating ENTR-601-44 for the potential treatment of individuals with Duchenne muscular dystrophy who are exon 44...
Read More
August 7, 2023

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne

Entrada announces authorization for its CTIMP for a Phase 1 clinical trial in healthy volunteers for ENTR-601-44
Read More
January 10, 2023

Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne who are Exon 45 Skipping Amenable

Entrada announces the selection of a second clinical candidate within its Duchenne franchise, ENTR-601-45
Read More
December 21, 2022

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

Entrada announces clinical hold notice from U.S. FDA regarding IND for ENTR-601-44
Read More

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

Gold Transparency 2022 Candid. Logo
Sitemap
© 2024 All rights reserved. Powered by Getfused

Support Jett Foundation

Donate Today
Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*) 





    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Register Now

    Experience the magic this summer!

    Apply Today

    How is the rare disease community accomplishing goals?

    Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

    Register Today

    Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

    Give Today

    Accessible Vehicle Fund Applications Open

    Apply Today